Could Tiny Rivals Make Gilead, Novartis Obsolete In Oncology? – Investor’s Business Daily
Investor’s Business Daily |
Could Tiny Rivals Make Gilead, Novartis Obsolete In Oncology?
Investor’s Business Daily Novartis and Gilead are still in the early stages of launching their respective drugs called Kymriah and Yescarta, which are known as CAR–T drugs. But Cellectis (CLLS) and Crispr Therapeutics (CRSP) — each with a tiny fraction of their rivals’ market … |
MD Magazine |
The Gene Therapy Dam is Finally Breaking
MD Magazine When Stephan Grupp, MD, PhD, began enrolling patients in the clinical trials for what would become the first-ever gene therapy approved by the US Food and Drug Administration (FDA), his problem wasn’t finding volunteers — it was reigning in … |
|
Evaluating CAR T-Cell Therapy Use
OncLive And we’ve used the strategy of rescuing patients who are having progressive disease during the early phases of CAR T-cell therapy while there’s actually expansion of T cells in the blood. Interestingly, what we’ve seen is expansion in patients who … |